These results were just presented at ASCO, the premiere oncology conference in the world.
The authors received a long standing ovation after the talk was over… a rare occurrence.
In patients with metastatic pancreatic cancer who had failed first-line treatment, 1 year survival went from 18.7% on standard of care second-line chemotherapy to 53.3% on this new RAS inhibitor drug daraxonrasib.
It’s a major breakthrough in a disease that is considered a death sentence.
Link to the full journal paper that was simultaneously published in NEJM:
Paper · N Engl J Med · 2026Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancernejm.orgQuoted:
Full results of the 500-person trial, which tested the once-daily pill against standard chemotherapy in patients who had failed one round of chemotherapy, showed that daraxonrasib reduced the overall risk of death by 60% compared with patients with advanced pancreatic cancer treated with chemotherapy.
The treatment also halted or reversed tumor progression by nearly a third overall compared with just 10% in those given chemotherapy, according to results of the study which were presented on Sunday at the American Society of Clinical Oncology.
"It ticks all of the boxes," said Dr. Rachna Shroff, University of Arizona Cancer Center and ASCO expert in pancreatic cancer, saying that a doubling of survival and reduction in the risk of death has never been seen in patients whose cancer progressed after chemotherapy.
Preliminary results released on April 13 showed the drug reduced the time from diagnosis to a patient's death to 13.2 months versus 6.7 months for those on standard chemotherapy, sending shares of the company up 40%.
"These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer," said Dr. Brian Wolpin of Harvard's Dana-Farber Cancer Institute and principal investigator of the trial.
Quoted:
Daraxonrasib is the first in a new class of drugs called RAS(ON) inhibitors targeting variants of the RAS gene that drive cancer growth.
In patients with a known RAS mutation called G12, tumors remained under control for a median of 7.3 months among those on daraxonrasib versus 3.5 months with chemotherapy. The result was similar in the overall population.
The percentage of patients whose cancer shrank or disappeared was about 33.2% in patients with the G12 mutation versus about 11.8% in the chemotherapy arm. In the overall population, 31.6% of patients saw their tumors shrink or disappear compared with 11.2% who received chemotherapy.
Rash was the most frequent severe side effect, occurring in 14% of patients, followed by stomatitis or mouth sores and inflammation, which occurred in 12% of patients.
Just 1.2% of patients given daraxonrasib dropped out of the trial because of side effects, compared with 11.2% among those who were on chemotherapy.
#pancreaticcancerHD #cancerHD
#daraxonrasibHD #ascoHD #rasHD #rasolute302HD
